Drugs

Rami Manochakian: U.S. FDA approves adjuvant Alectinib in patients with stage IB-IIIA ALK+Non-Small Cell Lung Cancer

Photo from Rami Manochakian/X

Apr 26, 2024, 10:07

Rami Manochakian: U.S. FDA approves adjuvant Alectinib in patients with stage IB-IIIA ALK+Non-Small Cell Lung Cancer

Rami Manochakian, Associate Professor and Thoracic Oncologist at Mayo Clinic, shared on X/Twitter:

”HOT OFF THE PRESS.

BIG NEWS.

U.S. FDA approves adjuvant Alectinib following surgery in patients with stage IB-IIIA ALK+ Non-Small Cell Lung Cancer based on results of Alina trial:

High DFS HR: 0.24 (compared with adjuvant chemotherapy).”

Read further.
Source: Rami Manochakian/X

adjucant alectinib alectinib ALINA trial ALK Positive Lung CancerK cancer Cancer research chemotherapy clinical trial FDA approval Lung cancer Mayo Clinic non small cell lung cancer NSCLC OncoDaily Oncology Rami Manochakian U.S. FDA

Invest in Health Policy: A Conversation with Professor Andreas Charalambous

FDA Approves Cosibelimab-ipdl for Treatment of Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma

Dolph Lundgren’s Fight for Life: How He Survived Kidney Cancer After 9 Years of Battle

Agenus and Tanner Pharma Partner to Expand Global Access to BOT/BAL

Bispecific Antibody M701 Offers a Novel Treatment Option for Malignant Ascites

Special Coverage